|
Drug discovery and development company SCYNEXIS, Inc. announced the pricing of its initial public offering of 6,200,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by SCYNEXIS. In addition, SCYNEXIS has granted the underwriters a 30-day option to purchase up to an additional 930,000 shares of common stock at the initial public offering price less the underwriting discounts and commissions to cover over-allotments, if any. The company's shares are expected to begin trading on The NASDAQ Global Market on May 2, 2014, under the ticker symbol "SCYX". RBC Capital Markets and Canaccord Genuity are acting as joint book-running managers. JMP Securities is participating as lead manager in the offering.
